The abstract is read at the publisher; the summary is JClub's.
In 15 participants with metabolic dysfunction-associated steatotic liver disease, 6-week PF-06835919 ketohexokinase inhibition improves hepatic insulin sensitivity and lowers intrahepatic lipid and saturated fatty acid content.
- Why it matters: Fructose intake is linked to cardiometabolic disease, but it is unclear whether blocking the first step of fructose metabolism can improve metabolic function in MASLD beyond the liver.
- What they did: In a randomized, placebo-controlled crossover trial, participants received PF-06835919 for 6 weeks; hepatic insulin sensitivity was assessed by insulin-stimulated suppression of endogenous glucose production, with secondary measures of insulin sensitivity, fat distribution, and fat oxidation.
- The result: PF-06835919 did not change body weight, but it improved insulin-stimulated glucose disposal, adipose tissue insulin sensitivity and distribution, and nocturnal fat oxidation, alongside shifts in VLDL particle size distribution and circulating hepatokines.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.